In NSCLC, the success of Erlotinib was, in part, due to the response association to certain EGFR mutations, but no such molecular subgroup or predictive response marker could be established for PDAC (Tzeng et al, 2007). Here, EGFR is linked to non-small cell lung carcinoma.